Inovio Pharma (INO) Misses Q4 EPS by 6c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.29 --0%
EPS Growth %: +75.9%
Financial Fact:
Loss from operations: -20.2M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +75.9%
Financial Fact:
Loss from operations: -20.2M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.34), $0.06 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.39 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Oppenheimer Starts Teva Pharma (TEVA) at Outperform
- Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
